Abstract:Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19 genetic polymorphisms and inflammation on voriconazole pharmacokinetics have not been considered in previous population pharmacokinetic (PPK) studies, especially in the Chinese population. This study aimed to analyze the impact of inflammation on the pharmacokinetics of voriconazole in patients with different CYP2C19 genotypes and optimize the dosage of administration. Data were obtained retrospectively from adult patients aged ≥16 years who received voriconazole for invasive fungal infections from October 2020 to June 2023. Plasma voriconazole levels were measured via high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). CYP2C19 genotyping was performed using the fluorescence in situ hybridization method. A PPK model was developed using the nonlinear mixed-effect model (NONMEM). The final model was validated using bootstrap, visual predictive check (VPC), and normalized prediction distribution error (NPDE). The Monte Carlo simulation was applied to evaluate and optimize the dosing regimens. A total of 232 voriconazole steady-state trough concentrations from 167 patients were included. A one-compartment model with first order and elimination adequately described the data. The typical clearance (CL) and the volume of distribution (V) of voriconazole were 3.83 L/h and 134 L, respectively. The bioavailability was 96.5%. Covariate analysis indicated that the CL of voriconazole was substantially influenced by age, albumin, gender, CRP, and CYP2C19 genetic variations. The V of voriconazole was significantly associated with body weight. An increase in the CRP concentration significantly decreased voriconazole CL in patients with the CYP2C19 normal metabolizer (NM) and intermediate metabolizer (IM), but it had no significant effect on patients with the CYP2C19 poor metabolizer (PM). The Monte Carlo simulation based on CRP levels indicated that patients with high CRP concentrations required a decreased dose to attain the therapeutic trough concentration and avoid adverse drug reactions in NM and IM patients. These results indicate that CRP affects the pharmacokinetics of voriconazole and is associated with the CYP2C19 phenotype. Clinicians dosing voriconazole should consider the patient's CRP level, especially in CYP2C19 NMs and IMs.

Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients

Use of Monte Carlo simulation to estimate the influence of CYP2C19 polymorphism on dosage regimen of voriconazole in patients with invasive fungal infection

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Predictors Of Adverse Events And Determinants Of The Voriconazole Trough Concentration In Kidney Transplantation Recipients

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients

Individualized Treatment with Voriconazole in the Chinese Population: Inflammation Level As a Novel Marker for Dose Optimization.

The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals

The Importance of CYP2C19 Genotype in Tacrolimus Dose Optimization when Concomitant with Voriconazole in Heart Transplant Recipients

[CYP2C19 Genetic Polymorphism and Monitoring Voriconazole Plasma Concentrations in the Treatment and Prevention of Invasive Fungal Disease for Hematological Patients].

The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study

Combined Impact of Hypoalbuminemia and Pharmacogenomic Variants on Voriconazole Trough Concentration: Data from a Real-Life Clinical Setting in the Chinese Population.

Efficacy and Safety of Voriconazole and Cyp2c19 Polymorphism for Optimised Dosage Regimens in Patients with Invasive Fungal Infections

Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole

Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing

Effects of Cytochrome P450 3A4 and Non-Genetic Factors on Initial Voriconazole Serum Trough Concentrations in Hematological Patients with Different Cytochrome P450 2C19 Genotypes.

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization

Interactive Effects of Glucocorticoids and Cytochrome P450 Polymorphisms on the Plasma Trough Concentrations of Voriconazole

Predictors of tacrolimus dose optimization when drug-drug interaction associated with voriconazole in heart transplant recipients

Correlation of CYP2C19 Genotype with Plasma Voriconazole Exposure in South-western Chinese Han Patients with Invasive Fungal Infections.